Matt Hoffman

Siponimod (Mayzent; Novartis) improved Symbol Digit Modalities Test scores in patients at 12, 18, and 24 months compared to placebo.

The DMD treatment pipeline boasts a number of therapeutics with varying mechanisms of action and delivery systems, pointing to a promising future for treatment.

The calcium, magnesium, potassium, and sodium oxybates solution, marketed as Xywav, was approved for cataplexy and daytime sleepiness in narcolepsy in July 2020.

ElectroCore announced that the expanded indication, noting that gammaCore is now the only acute and preventive option approved for both adult and adolescent migraine.

With promising data presented at WORLDSymposium 2021 and a PDUFA date looming in May, investigator Priya S. Kishnani, MD, offered her insight on Sanofi’s investigational therapy.

The data revealed some of the more common and problematic symptoms, challenges, and comorbidities that persist for these individuals despite care.

Data presented at WORLDSymposium 2021 suggest that the Sanofi enzyme replacement therapy is effective and safe compared to the company’s other agent, alglucosidase alfa.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive conversation with Scott Perry, MD; Orrin Devinsky, MD; and Tracy Salazar, PhD.

Data from a small study showed patients experienced significant improvements in MDS-UPDRS III scores after 4 months of treatment with single-hemisphere FUS.

Wildon Farwell, MD, MPH, shed some light on the ongoing phase 4 trial and what clinical insights might be gleaned from the data.

Study results suggest that fewer than 10% of the more than 2000 migraine episodes analyzed were associated with increased levels of perceived stress.

The Cassava Sciences agent showed 6-month improvements in both ADAS-Cog and NPI scores, and a phase 3 trial is expected to begin in late 2021.

Neurocrine Biosciences and Voyager Therapeutics have terminated the Parkinson disease portion of their partnership, ending development for VY-AADC, also known as NBIb-1817.

After Theranica’s remote electrical neuromodulation was approved for those aged 12 years and older with migraine, study investigator Jennifer McVige, MD, MA, shared her insight.

The investigational agent developed by Biogen and Eisai is now expected to receive regulatory review by June 7, 2021.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive conversation between an expert neurologist, psychologist, patient, and care partner on various facets of multiple sclerosis.

Rafael Carbunaru, PhD, MSc, vice president, research and development, Neuromodulation, Boston Scientific, discussed the system’s recent FDA approval.

This fourth-generation system since 2012 is indicated as adjunctive therapy for stimulation of the subthalamic nucleus and internal globus pallidus to treat Parkinson symptoms.

Maha Radhakrishnan, MD, the Group SVP and chief medical officer at Biogen, discussed the collaborative study between Biogen and Apple that’s expected to kick off later this year.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jacqueline French, MD.

The investigation identified 13 novel and significant associations with cerebrovascular disease and transient cerebral ischemia.

The GW Pharmaceuticals product resulted in nearly 50% reductions in seizures at both 25 mg/kg and 50 mg/kg dose groups.

An analysis of MSBase data including more than 14,000 patients with MS suggests that disease-modifying therapies are effective in improving disability outcomes in relapsing disease.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Leigh Charvet, PhD.

Increasing the use and accessibility of mechanical thrombectomy may reduce the burden of stroke on a global scale.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jennifer Frontera, MD, and a number of others.

In a NeurologyLive® Peer Exchange, a panel of migraine specialists discussed the novel therapies in development and those entering the market for the treatment of acute migraine.

The Merz Therapeutics product, marketed as Xeomin, is the first and only FDA-approved neuromodulator available for patients aged 2 years and older with chronic sialorrhea.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive look into the discussion surrounding aducanumab and how it reflects the challenges of conducting clinical trials in Alzheimer disease.

Treating Alzheimer disease presents a spiderweb of complexity for physicians, and its intricacies have made assessing therapies equally puzzling.